Candidate genetic variants included in a genetic risk algorithm may not meet standards of reasonable clinical efficacy in identifying opioid use disorder risk, according to a study published in JAMA ...

New Monash University research has revealed a concerning rise in new opioid prescriptions among younger Victorians, while ...

More New Yorkers received scripts for buprenorphine, a med used to treat opioid addiction, amid fight against record-high ...

An online-based mindfulness treatment program significantly reduced opioid craving among participants with opioid use disorder results from a randomized clinical trial published in JAMA Network Open ...

Opioid-related neurocognitive symptoms among patients on long-term opioid therapy were most prevalent during the course of therapy.

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...

Along with this increase, there has been a jump both in ER visits by people of all age groups who have inadvertently taken ...

On Jan. 30, the U.S. Food and Drug Administration (FDA) approved a new drug called suzetrigine to treat moderate-to-severe ...

The story of Hamilton County is the story of much of America in 2025. Overdose deaths have fallen sharply, offering hope the ...

NSDUH only queried opioid misusers about opioid use disorder symptoms. After they changed the protocol and asked all ...

When a child develops a brain tumor, early diagnosis is essential. Alan Cohen, M.D., director of pediatric neurosurgery at Johns Hopkins Children’s Center, shares the most common signs and symptoms ...

Background: Primary care is the initial contact point for most patients with opioid use disorder (OUD) but lacks tools for guiding treatment. Only a small fraction of patients access evidence-based ...